User:Mr. Ibrahem/Benazepril

Mr. Ibrahem/Benazepril
Clinical data
Pronunciation	/bəˈnæzəprɪl/
Trade names	Lotensin, others
AHFS/Drugs.com	Monograph
MedlinePlus	a692011
Pregnancy; category	D;
Routes of; administration	By mouth
Drug class	ACE inhibitor
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Protein binding	96.7%
Metabolism	Liver glucuronidation
Elimination half-life	10 hours
Excretion	Kidney and biliary
Identifiers
	IUPAC name 2-[(3S)-3-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-2-oxo-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid;
Chemical and physical data
Formula	C24H28N2O5
Molar mass	424.497 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(OCC)[C@@H](N[C@@H]2C(=O)N(c1ccccc1CC2)CC(=O)O)CCc3ccccc3;
	InChI InChI=1S/C24H28N2O5/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28)/t19-,20-/m0/s1 ; Key:XPCFTKFZXHTYIP-PMACEKPBSA-N ;
	(verify)

Benazepril, sold under the brand name Lotensin among others, is a medication used to treat high blood pressure, heart failure, and diabetic kidney disease.^[1] It is a reasonable initial treatment for high blood pressure.^[1] It is taken by mouth.^[1] Versions are available as the combinations benazepril/hydrochlorothiazide and benazepril/amlodipine.^[1]

Common side effects include feeling tired, dizziness, cough, and light-headedness with standing.^[1] Serious side effects may include kidney problems, low blood pressure, high blood potassium, and angioedema.^[1] Use in pregnancy may harm the baby while use when breastfeeding maybe okay.^[4] It is an ACE inhibitor and works by decreasing renin-angiotensin-aldosterone system activity.^[1]

Benazepril was patented in 1981 and came into medical use in 1990.^[5] It is available as a generic medication.^[1] A month supply in the United States costs about US$1.32 as of 2019.^[6] In 2017, it was the 104th most commonly prescribed medication in the United States, with more than seven million prescriptions.^[7]^[8]

References[edit]

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k "Benazepril Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
^ Benowitz, Neal L. (2020). "11. Antihypertensive agents". In Katzung, Bertram G.; Trevor, Anthony J. (eds.). Basic and Clinical Pharmacology (15th ed.). New York: McGraw-Hill. p. 183. ISBN 978-1-260-45231-0.
^ "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 6 September 2020.
^ "Benazepril Pregnancy and Breastfeeding Warnings". Drugs.com. Retrieved 3 March 2019.
^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 468. ISBN 9783527607495.
^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.
^ "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
^ "Benazepril Hydrochloride - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.

[AHFS2019-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k "Benazepril Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.

[Katzung2021-2] Benowitz, Neal L. (2020). "11. Antihypertensive agents". In Katzung, Bertram G.; Trevor, Anthony J. (eds.). Basic and Clinical Pharmacology (15th ed.). New York: McGraw-Hill. p. 183. ISBN 978-1-260-45231-0.

[WHO2020DDD-3] "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 6 September 2020.

[Preg2019-4] "Benazepril Pregnancy and Breastfeeding Warnings". Drugs.com. Retrieved 3 March 2019.

[Fis2006-5] Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 468. ISBN 9783527607495.

[NADAC2019-6] "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.

[ref-7] "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.

[ref1-8] "Benazepril Hydrochloride - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.

[1]

[2]

[4]

[5]

[6]

[7]

[8]